Pliant Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases. The company's lead candidate includes bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which has completed phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325, a phase 1-ready program for treatment of the muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Pliant Therapeutics (PLRX – Research Report), Rocket Pharmaceutic...

Current Quarter	$-0.49	Next Quarter	$-0.52
Current Year	$-2.64	Next Year	$-2.83
QoQ Growth	-6.1%	YoY Growth	-7.2%
3Y EPS CAGR	N/A	Target Price	$2.96
Consensus	Buy	Upside	+77.2%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PLRX	$1.67	+3.09%	392.25K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PLRX	$1.67	+3.1%	392.25K
3
4
5
6

PLRX

PLRX

EPS Estimates Overview

Quarterly EPS Estimates

Revenue Analysis

Get PLRX Data in Excel

Get PLRX Data in Excel